Management of Raynaud's phenomenon and digital ischemia

Current Rheumatology Reports

Volumn 15, Issue 1, 2013, Pages

  Herrick, Ariane L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Botulinum toxin; Clinical trials; Critical ischemia; Digital ischemia; Digital ulcers; Endothelin 1 receptor antagonists; Glyceryl trinitrate; Management; Nailfold capillaroscopy; Phosphodiesterase inhibitors; Prostanoids; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

PHOSPHODIESTERASE INHIBITOR;

FINGER; HUMAN; ISCHEMIA; RAYNAUD PHENOMENON; REVIEW; SKIN ULCER; SYSTEMIC SCLEROSIS; VASCULARIZATION;

FINGERS; HUMANS; ISCHEMIA; PHOSPHODIESTERASE INHIBITORS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN ULCER;

MLCS; MLOWN;

EID: 84878369896     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0303-1     Document Type: Article

References (50)

1. Silman A, Holligan S, Brennan P, Maddison P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ. 1990;301:590-2. (Pubitemid 20346538)
2. Tiev KP, Diot E, Clerson P, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIRSclerodermie). J Rheum. 2009;36:1470-6.
3. Khimdas S, Harding S, Bonner A, et al. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group Registry. Arthritis Care Res. 2011;63:142-9.
4. Mouthon L, Mestre-Stanislas C, Berezne A, et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis. 2010;69:214-7.
5. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485-8.
6. Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 2005;52:1259-63. (Pubitemid 40530134)
7. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620-8.
8. Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2012; Issue 7. Art. No.: CD006687. doi: 10.1002/14651858.CD006687.pub3.
9. Huissstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil. 2011;92:1166-80.
10. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatol. 2010;49:2420-8.
11. Herrick AL, Van den Hoogen F, Gabrielli A, et al. Modified- Release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011;63:775-82.
12. Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 2012;172:1182-4.
13. Pope J, Harding S, Khimdas S, et al. Agreement with guidelines from a large database for management for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. J Rheumatol. 2012;39:524-31.
14. Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails - a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42:42-55.
15. Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon. Arthritis Rheum. 2009;60:870-7.
16. Fava A, Wung PK, Wigley FM, et al. Efficacy of Rho Kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res. 2012;64:925-9.
17. Bredie SJ, Jong MC. No significant effect of Ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012;59:215-21.
18. Malenfant D, Summers K, Seney S, et al. Result of a pilot randomized placebo-controlled trial in primary and secondary Raynaud's phenomenon with St. John's Wort: detecting changes in angiogenic cytokines when RP improves. ISRN Rheumatol 2011; Article ID 580704, 6 pages. doi:10.5402/2011/580704.
19. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199-206.
20. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews 1998; Issue 2: CD000953. doi: 10.1002/14651858
21. Walker KM, Pope J. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol. 2011;38:1326-8.
22. Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterial sympathectomy. J Hand Surg (American). 2009;34:1454-60.
23. Korn JH, Mayes M, Matucci Cerinic M, for the RAPIDS-1 Study Group, et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-93. (Pubitemid 39643947)
24. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebocontrolled trial. Ann Rheum Dis. 2011;70:32-8.
25. Arefiev K, Fiorentino DF, Chung L. Endothelin receptor antagonists for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Int J Rheumatol 2011; Article ID 201787, 7 pages, doi: 10.1155/2011/201787.
26. Ivorra JA, Simeon CP, Sancho JJ, et al. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study. J Rheumatol. 2011;38:1631-5.
27. Nagai Y, Hasegawa M, Hattori T, et al. Bosentan for digital ulcers in patients with systemic sclerosis. J Dermatol. 2012;39:48-51.
28. Ichimura Y, Asano Y, Hatano M, et al. Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. Mod Rheumatol. 2011;21:548-52.
29. Taniguchi T, Asano Y, Hatano M, et al. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. Br J Dermatol. 2012;166:417-21.
30. Nguyen VA, Eisendle K, Gruber I, et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatol. 2010;49:583-7.
31. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010;69:1475-8.
32. Della Rossa A, Doveri M, D'Ascanio A, et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol. 2011;40:323-5.
33. Moinzadeh P, Hunzelmann N, Kreig T. Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis. J Am Acad Dermatol. 2011;65:e102-4.
34. Seibold JR, Wigley FM, Schiopu E, et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study (abstract). Arthritis Rheum. 2010;63(Suppl):S968-9.
35. Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Sem Arthritis Rheum. 2012;41:599-603.
36. Stone AV, Koman LA, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg (American Volume). 2012;37:795-802.
37. Yoshimasu T, Ikeda T, Uede K, et al. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. J Dermatol. 2012;39:536-40.
38. Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, et al. Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis. 1994;53:323-6. (Pubitemid 24164976)
39. Hasegawa M, Nagai Y, Tamura A, Ishikawa O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol. 2006;155:1159-64. (Pubitemid 44729989)
40. Zhang W, Xu JR, Lu Q, et al. High-resolution magnetic resonance angiography of digital arteries in SSc patients on a 3 Tesla: preliminary study. Rheumatol. 2011;50:1712-9.
41. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902-12.
42. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70:476-81.
43. Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis-spectrum disorders. Arthritis Rheum. 2010;62:2595-604.
44. Sebastiani M, Manfredi A, Colaci M, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum (Arthritis Care Res). 2009;61:688-94.
45. Smith V, De Keyser F, Pizzorni C, et al. Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis. 2011;70:180-3.
46. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol. 2008;35:1801-8.
47. Gabrielli A, Svegliati S, Moroncini G, et al. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol. 2008;30:329-37.
48. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-5. (Pubitemid 41612301)
49. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med. 2006;166:231-3. (Pubitemid 43144949)
50. Schiopu E, Hsu VM, Impens AJ, et al. Randomised placebocontrolled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36:2264-8.